Clinical Trial

A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The primary purpose of this study is to evaluate the optimal doses of E2086 compared to placebo in participants with narcolepsy for reduction of excessive daytime sleepiness (EDS) as assessed by Mean Sleep Latency (MSL) (measured from the first 4 maintenance of wakefulness tests \[MWTs\]).
Protocol Amendment History 2 changes
critical Recruitment opened 2026-05-15
notable Trial sites expanded: 0 -> 57 locations 2026-05-15
Trial Details
NCT Number NCT07493265
Lead Sponsor Eisai Inc.
Conditions Narcolepsy
Enrollment 64 participants
Start Date 2026-03-26
Primary Completion 2027-02-14 (estimated)
Study Completion 2027-03-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-14